Name: Measles, Mumps and Rubella (MMR) Vaccines Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH4709
Price: 4350 USD
Availability: InStock

Measles, Mumps and Rubella Vaccines Market Size, Share & Report 2030

Measles, Mumps and Rubella (MMR) Vaccines Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Measles, Mumps and Rubella (MMR) Vaccines Market is Segmented By Type (MMR, MMRV, Others), By End-User (Hospitals, Vaccination Centre, Clinics, Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

<blockquote>
Measles, Mumps, and Rubella (MMR) Vaccines Market&nbsp;is estimated to reach high CAGR during the forecast period (2023-2030).
</blockquote>

The MMR vaccine protects against measles, mumps, and rubella. The first dose is usually given to children between the ages of 9 and 15 months, and the second dose is usually given to children between the ages of 15 and 6 years, with at least 4 weeks between doses.

Measles, Mumps and Rubella (MMR) Vaccines Market

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			Measles, Mumps, and Rubella (MMR) Vaccines Market is estimated to reach high CAGR during the forecast period (2022-2029).
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Type, By End-User, and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

To Get a Free Sample&nbsp;<a href="https://www.datamintelligence.com/download-sample/measles-mumps-and-rubella-vaccines-market">Click here</a>

<h3>Measles, Mumps and Rubella (MMR) Vaccines Market Dynamics</h3>

The factors driving the global measles, mumps, and rubella (MMR) vaccines are the increasing demand for vaccine and vaccination programs by the government is expected to drive the market growth.

The increasing demand for vaccine and vaccination programs by the government is expected to drive market growth in the forecast period

Vaccine manufacturers are collaborating with organizations such as WHO, UNICEF, and the GAVI Alliance to improve their vaccination programs to reach the greatest number of people with vaccines. Despite several government initiatives, measles remains a leading cause of death among children under five. As a result, increasing the success rate of vaccination programs is dependent on each country&#39;s government initiatives. In order to reduce the prevalence of these diseases, some organizations are focusing on initiatives. GAVI Alliances, for instance, has launched a vaccination campaign in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria, and Pakistan.

Similarly, in 2017, the Government of India launched a Pan-India Measles-Rubella vaccination campaign in which children aged 9 months to 15 years are vaccinated in order to reduce the prevalence of these diseases in children. Such initiatives by various organizations and governments are expected to drive market growth.

The side effects associated with vaccination is expected to hamper the market growth

MMR vaccination can result in a sore arm from the injection or redness where the shot is given, fever, and a mild rash. Swelling of the glands in the cheeks or neck and temporary pain and stiffness in the joints (mostly in adolescent or adult women) can occur following MMR vaccination. Serious reactions are uncommon. These can include seizures (frequently associated with fever) or a temporary low platelet count, resulting in unusual bleeding or bruising. This vaccine may cause a potentially fatal infection in people with compromised immune systems. People who have severe immune system problems should not receive the MMR vaccine.

<h3>COVID-19 Impact Analysis</h3>

During the COVID-19 pandemic, national and international health agencies advised that immunization services be maintained indefinitely due to the possibility of a resurgence of vaccine-preventable diseases, either controlled or eliminated, as a result of low vaccination coverage. However, studies have shown that, in an attempt to reduce the risk of transmission of SARS-CoV-2, the etiological agent of COVID-19, social isolation measures have reduced vaccination programs in children and adolescents in several countries and regions around the world.

For instance, the MMR vaccine, made from live attenuated measles, rubella, and mumps viruses, is free in Brazil and is recommended for routine vaccination at 12 months and 9 years of age. The historical decrease in MMR vaccine coverage rates in Brazil may have been hampered by sanitary measures implemented in response to the COVID-19 pandemic, the distribution of health services, and the allocation of health resources in Brazil affected by COVID-19.

<h3>Measles, Mumps and Rubella (MMR) Vaccines Market Segment Analysis</h3>

MMR II (measles, mumps, and rubella virus vaccine live) segment is expected to dominate the market growth in the forecast period

M-M-R II is a combination vaccine protecting against measles, mumps, and rubella (MMR). M-M-R II is a sterile lyophilized preparation of ATTENUVAX (Measles Virus Vaccine Live), a more attenuated line of measles virus derived from Enders&#39; attenuated Edmonston strain and propagated in chick embryo cell culture; MUMPSVAX (Mumps Virus Vaccine Live), the Jeryl Lynn (B level) strain of mumps virus propagated in a chick.

Furthermore, M-M-R II comprises weakened strains of live measles, mumps, and rubella viruses. These live virus strains cause either mild or no symptoms of infection. The body responds by producing disease-fighting substances (antibodies) against these infections when the vaccine is given. When a vaccinated child comes into contact with the measles, mumps, or rubella virus, the body is usually ready to destroy it and produces antibodies. However, as with all vaccines, there is no guarantee of complete protection against measles, mumps, and rubella. Furthermore, maximum protection may take up to 4-6 weeks to develop so that infections may occur during this time.

Global Measles, Mumps and Rubella (MMR) Vaccines Market- Geographical Analysis

North America region is expected to hold the largest market share in the global measles, mumps, and rubella (MMR) vaccines market

The growing prevalence of measles, mumps, and rubella and the increasing government vaccination programs in this region are expected to drive the market growth.

In the United States, 371 cases of measles were confirmed in 2018. The Centers for Disease Control and Prevention (CDC) confirmed 1215 cases across 30 states from January to August 2019. In conjunction with mass immunization campaigns in countries with high case and death rates, routine measles vaccination for children is a critical public health strategy for reducing global measles deaths. For nearly 60 years, the measles vaccine has been in use. It is risk-free, efficient, and inexpensive. A child&#39;s immunization against measles costs about one dollar in the United States. The availability of vaccines in this region is expected to boost market growth. For instance, in the United States, two vaccines containing the measles, mumps, and rubella virus are approved for use. The M-M-R II vaccine protects against measles, mumps, and rubella (MMR). ProQuad is a vaccine that protects against measles, mumps, rubella, and varicella (MMRV)

Measles, mumps, and rubella (MMR) vaccines market are moderately competitive, increasing company collaborations, clinical trials, acquisitions, and product launches. Some of the key players in the market are GlaxoSmithKline plc, Merck &amp; Co. Inc. and Serum Institute of India Ltd, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited.

GlaxoSmithKline plc

Overview: GlaxoSmithKline is a science-led global healthcare company. It is the world&rsquo;s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. GlaxoSmithKline pharmaceuticals have a broad portfolio of innovative and established HIV, respiratory, immuno-inflammation, and oncology medicines. The company was founded in 2000.

Product Portfolio: Priorix is a lyophilized mixture of the attenuated viruses Schwarz measles, RIT 4385 mumps (derived from the Jeryl Lynn strain), and Wistar RA 27/3 rubella. The vaccine&#39;s measles and mumps components are made in chick embryo cell culture and may contain traces of egg protein. It is indicated to protect against measles, mumps, and rubella.

Key Developments: On August 2nd, 2021, GlaxoSmithKline submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its Priorix vaccine, seeking approval for use in active immunization against measles, mumps, and rubella infection (MMR). If approved, the Priorrix vaccine would provide an alternative MMR vaccine to healthcare providers in the United States.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Frequently Asked Questions</h3>

What is the Projected CAGR value of the Measles, Mumps and Rubella (MMR) Vaccines Market?

Measles, Mumps, and Rubella (MMR) Vaccines Market is estimated to reach high CAGR during the forecast period (2022-2029).

Which region controlled the global market during 2022-2029?

North America&nbsp;region Controls&nbsp;the&nbsp;Measles, Mumps and Rubella (MMR) Vaccines Market&nbsp;during 2022-2029

Which is the fastest growing region in the Measles, Mumps and Rubella (MMR) Vaccines Market?

Among all regions,&nbsp;Asia Pacific&nbsp;is the fastest growing market share during the forecast period&nbsp;

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/pet-food-market">Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/organic-pet-food-market">Organic Pet Food Market</a>

<a href="https://www.datamintelligence.com/research-report/freeze-dried-pet-food-market">Freeze-Dried Pet Food Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3>Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3>Market Definition and Overview</h3>
	</li>
	<li>
	<h3>Executive Summary</h3>

	<ol>
		<li>Market Snippet By Type</li>
		<li>Market Snippet By End User</li>
		<li>Market Snippet By Region</li>
	</ol>
	</li>
	<li>
	<h3>Market Dynamics</h3>

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers:
			<ol>
				<li>The increasing demand for vaccine and vaccination programs by the government</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>The side effects associated with vaccination</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Industry Analysis</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Epidemiology Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>
	<h3>COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3>By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>MMR*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
			<li>M-M-R II</li>
		</ol>
		</li>
		<li>MMRV
		<ol>
			<li>ProQuad</li>
		</ol>
		</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By End User</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Attractiveness Index, By End User</li>
		</ol>
		</li>
		<li>Hospitals
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Clinics</li>
		<li>Vaccination Centre</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3>By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3>Competitive Landscape</h3>

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>
	<h3>Company Profiles</h3>

	<ol>
		<li>GlaxoSmithKline plc*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Merck &amp; Co. Inc.</li>
		<li>Serum Institute of India Ltd</li>
		<li>Daiichi Sankyo Company, Limited.</li>
		<li>Takeda Pharmaceutical Company Limited.(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3>DataM Intelligence&nbsp;</h3>

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 01 Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 02 Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 03 Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2021, 2025 &amp; 2029($ Million)

Table 04&nbsp; Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2019-2029 ($ Million)

Table 05 Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2021, 2025 &amp; 2029($ Million)

Table 06&nbsp; Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2019-2029 ($ Million)

Table 07 Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Region, 2021, 2025 &amp; 2029($ Million)

Table 08&nbsp; Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Region, 2019-2029 ($ Million)

Table 09&nbsp; North America Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2019-2029 ($ Million)

Table 10 North America Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2019-2029 ($ Million)

Table 11&nbsp; North America Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 12 South America Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2019-2029 ($ Million)

Table 13 South America Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2019-2029 ($ Million)

Table 14 South America Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 15 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2019-2029 ($ Million)

Table 16 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2019-2029 ($ Million)

Table 17 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 18 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2019-2029 ($ Million)

Table 19 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2019-2029 ($ Million)

Table 20 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Country, 2019-2029 ($ Million)

Table 21 Middle East &amp; Africa Measles, Mumps and Rubella (MMR) Vaccines Market Value, By Type, 2019-2029 ($ Million)

Table 22 Middle East &amp; Africa Measles, Mumps and Rubella (MMR) Vaccines Market Value, By End User, 2019-2029 ($ Million)

Table 23 GlaxoSmithKline plc: Overview

Table 24 GlaxoSmithKline plc: Product Portfolio

Table 25 GlaxoSmithKline plc: Key Developments

Table 26 Merck &amp; Co. Inc.: Overview

Table 27 Merck &amp; Co. Inc.: Product Portfolio

Table 28 Merck &amp; Co. Inc.: Key Developments

Table 29 Serum Institute of India Ltd: Overview

Table 30 Serum Institute of India Ltd: Product Portfolio

Table 31 Serum Institute of India Ltd: Key Developments

Table 32 Daiichi Sankyo Company, Limited.: Overview

Table 33 Daiichi Sankyo Company, Limited.: Product Portfolio

Table 34 Daiichi Sankyo Company, Limited.: Key Developments

Table 35 Takeda Pharmaceutical Company Limited.: Overview

Table 36 Takeda Pharmaceutical Company Limited.: Product Portfolio

Table 37 Takeda Pharmaceutical Company Limited.: Key Developments

&nbsp;&nbsp; List of Figures

Figure 01 Global Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Type, 2021 &amp; 2029(%)

Figure 02 Global Measles, Mumps and Rubella (MMR) Vaccines Market Share, By End User, 2021 &amp; 2029(%)

Figure 03 Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 04 Global Measles, Mumps and Rubella (MMR) Vaccines Market Y-o-Y Growth, By Type, 2021-2029 (%)

Figure 05 MMR: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 06 MMRV: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 07 Others: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 08 Global Measles, Mumps and Rubella (MMR) Vaccines Market Y-o-Y Growth, By End User, 2021-2029 (%)

Figure 09 Hospitals: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 10 Clinics: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 11&nbsp; Vaccination Centre: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 12&nbsp; Others: Global Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 13&nbsp; Global Measles, Mumps and Rubella (MMR) Vaccines Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 14 North America Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 15&nbsp; North America Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Type, 2021 &amp; 2029(%)

Figure 16 North America Measles, Mumps and Rubella (MMR) Vaccines Market Share, By End User, 2021 &amp; 2029(%)

Figure 17&nbsp; North America Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Country, 2021 &amp; 2029(%)

Figure 18 South America Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 19 South America Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Type, 2021 &amp; 2029(%)

Figure 20 South America Measles, Mumps and Rubella (MMR) Vaccines Market Share, By End User, 2021 &amp; 2029(%)

Figure 21&nbsp; South America Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Country, 2021 &amp; 2029(%)

Figure 22 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 23 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Type, 2021 &amp; 2029(%)

Figure 24 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Share, By End User, 2021 &amp; 2029(%)

Figure 25 Europe Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Country, 2021 &amp; 2029(%)

Figure 26 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 27 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Type, 2021 &amp; 2029(%)

Figure 28 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Share, By End User, 2021 &amp; 2029(%)

Figure 29 Asia-Pacific Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Country, 2021 &amp; 2029(%)

Figure 30 Middle East &amp; Africa Measles, Mumps and Rubella (MMR) Vaccines Market Value, 2019-2029 ($ Million)

Figure 31&nbsp; Middle East &amp; Africa Measles, Mumps and Rubella (MMR) Vaccines Market Share, By Type, 2021 &amp; 2029(%)

Figure 32 Middle East &amp; Africa Measles, Mumps and Rubella (MMR) Vaccines Market Share, By End User, 2021 &amp; 2029(%)

Figure 33 GlaxoSmithKline plc: Financials

Figure 34 Merck &amp; Co. Inc.: Financials

Figure 35 Serum Institute of India Ltd: Financials

Figure 36 Daiichi Sankyo Company, Limited.: Financials